Recent studies show targeted epigenetic reprogramming with Yamanaka factors rejuvenates neurons, reversing cognitive decline in aged mice and reducing Alzheimer’s markers, with AI enhancing safe...
Partial OSK reprogramming rejuvenates engram neurons in aged mice, improving memory by over 50%, with recent studies enhancing safety and biotech firms advancing towards human trials. New research sho...
The FDA has greenlit the first human trial of ER-100, a partial epigenetic reprogramming therapy targeting age-related eye diseases, marking a pivotal step in anti-aging and regenerative medicine. A l...
Recent studies show small molecules efficiently mimic Yamanaka factors to reverse epigenetic aging, with clinical trials on the horizon, offering a safer alternative to gene therapies. Advancements in...
